University College London

University College London (UCL) spinout AstronauTx has closed a £48m ($61m) Series A financing to develop novel treatments for Alzheimer’s disease and other neurodegenerative disorders. The company was launched in 2019, initially to build on research from the Alzheimer’s Research UK UCL Drug Discovery Institute (UCL DDI). Protoplasmic astrocytes play an active role in neuronal […]

A potent anti-cancer therapy has been created using Nobel prize-winning “click chemistry”, in a new study by University College London (UCL) and Stanford University researchers. The study, published in Nature Chemistry, opens up new possibilities for how cancer immunotherapies might be built in future. The research team created an anti-cancer therapy with three components: one […]

Research services provider Domainex has secured a new, fully fitted, three-storey building in Unity Campus in Cambridgeshire, UK. Domainex first moved to Unity Campus in January 2022, taking 7,000 sq ft of laboratory space at Iconix 2 to provide a dedicated facility for its biology department and freeing up space at its closely located Chesterford […]

A global study, led by University College London (UCL) and University College London Hospitals (UCLH) and sponsored by Roche, has shown that the cancer immunotherapy atezolizumab significantly improved the overall survival of advanced stage non-small cell lung cancer (NSCLC) patients, when compared to single-agent chemotherapy. For the fittest patients with advanced stage NSCLC, first-line immunotherapy […]

UK researchers at the Francis Crick Institute, Imperial College London and AstraZeneca will advance the discovery of new ‘molecular glues’ to treat a range of different diseases, thanks to a £11.2 million combined investment. The investment includes a Prosperity Partnership grant from the Engineering and Physical Sciences Research Council (EPSRC) and matching funds from AstraZeneca. […]

Sania Therapeutics, a new company focused on developing genetic medicines for neural circuit dysfunction, has launched at the American Society of Gene & Cell Therapy (ASGCT) conference. The company’s approach combines adeno-associated viruses (AAV) in human neural circuits with tuneable conditionally-activated ion channels. This corrects dysfunctional neural excitation. Sania’s technology platforms were first developed at […]